title: [Pilot study-previously treated advanced non-small cell lung cancer].
abstract: This pilot study was performed to evaluate the safety and efficacy of weekly paclitaxel (TXL) administration by 1-hour infusion. A total of 10 patients with previously-treated advanced non-small cell cancer (NSCLC) were treated with weekly paclitaxel. TXL was administered weekly at a dose of 80 mg/m2, 3 times in a 4-week cycle, or 6 times in an 8-week cycle. A total of 6 patients achieved partial response, although no complete responses were observed. Median time to progression was 5 months (2-11 months). Grade 4 leukopenia occurred in one patient, and grade 3 neutropenia was observed in one patient. Severe non-hematological toxicity was uncommon; grade 1 neuropathy in 2 patients. This regimen had good clinical efficacy with low toxicity in outpatients with advanced NSCLC.
authors.affiliation: First Dept. of Internal Medicine, School of Medicine, Fukuoka University.
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Shirahama
authors.forename: Takamichi
authors.initials: T
authors.lastname: Aritomi
authors.forename: Sadanori
authors.initials: S
authors.lastname: Takeo
authors.forename: Kimihide
authors.initials: K
authors.lastname: Ando
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Wakamatsu
authors.forename: Midori
authors.initials: M
authors.lastname: Kumagawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Ichinose
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D010865:Pilot Projects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel